By: Philippa Roxby From: bbc.com Linda Kelly, 67, has advanced breast cancer which has spread to her bones and chest wall, but says a new pill has given her extra years of life and time to travel with her husband. “It does let you have a normal kind of life and you forget you have cancer,” she says of the …
Imlunestrant is a Viable Second-Line Option for Advanced HR-Positive, HER2-Negative Breast Cancer
By: Leah Lawrence From: docwirenews.com Certain patients with advanced estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that has progressed during or after aromatase inhibitor therapy with or without a CDK4/6 inhibitor may benefit from treatment with the oral selective ER degrader imlunestrant, according to results of the phase 3 EMBER-3 trial published in New …
Accessing Community Support and Resources for Breast Cancer Patients
By: Mercy Medical Center From: newswise.com Amber Geisler, LMSW, is an oncology social worker who sees patients in Mercy’s Institute for Cancer Care. Amber was interviewed by HealthCentral.com for a feature about how patients with metastatic breast cancer can access needed community support. Why is it so important for a patient with metastatic HER2-Low (or other forms of metastatic breast cancer) to have …
Vepdegestrant Demonstrates Progression-Free Survival in Patients With ER+/HER2- Metastatic Breast Cancer
From: pharmacytimes.com Vepdegestrant (ARV-471; Arvinas, Inc) met its primary end point of progression-free survival (PFS) compared with fulvestrant (Faslodex; AstraZeneca) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with CDK 4/6 inhibitors and endocrine therapy. The clinically meaningful outcomes were observed in the phase …
Central Nervous System Disease Drives Mortality in HER2+ Metastatic Breast Cancer Despite Longer Survival
By: Alexandra Gerlach From: .pharmacytimes.com Key Takeaways HER2+ MBC patients with CNS disease have longer overall survival than those with extracranial metastasis. CNS metastases in HER2+ breast cancer remain difficult to treat, requiring local therapies like radiotherapy. CNS progression is a major mortality cause in HER2+ MBC, highlighting the need for CNS-penetrant therapies. Clinical trials should include CNS disease patients …
FDA Fast Tracks Emiltatug Ledadotin in Advanced/Metastatic Breast Cancer
By: Jordyn Sava From: targetedonc.com The FDA has granted a new fast track designation to emiltatug ledadotin for the treatment of advanced or metastatic breast cancer, specifically targeting patients with HER2-low or HER2-negative disease, including TNBC.1 This designation applies to patients who have previously received a topoisomerase-1 inhibitor antibody-drug conjugate (ADC). Additionally, hormone-receptor positive patients must have either received prior …
New Research Approaches to Metastatic Breast Cancer
From: ascopost.com Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded in cultivating stable tumor organoids directly from blood …
Patients with heart disease may be at increased risk for advanced breast cancer
By: University of Texas M. D. Anderson Cancer Center From: /medicalxpress.com Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson Cancer Center, patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis CVD compared to those with early-stage …
Can Tumor Mutational Burden Guide Treatment in Metastatic Breast Cancer?
By: Greg Laub From: medpagetoday.com Hormone receptor-positive patients with high TMB may fare well with immunotherapy A studyopens in a new tab or window presented at the San Antonio Breast Cancer Symposiumopens in a new tab or window examined whether tumor mutational burden (TMB) was associated with outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer patients treated with either pembrolizumab …
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations
By: Azka Ali, MD, GuestRobert A. Figlin, MD, FACP From: oncologynewscentral.com Recent advances in hormone receptor–positive, HER2-negative metastatic breast cancer have led to questions about the timing of genetic testing and the optimal treatment choices for patients. “I, like many others, have changed my personal practice,” says Azka Ali, MD, a medical oncologist at the Cleveland Clinic Taussig Cancer Institute …